MX2015007916A - Peri-carbinoles. - Google Patents

Peri-carbinoles.

Info

Publication number
MX2015007916A
MX2015007916A MX2015007916A MX2015007916A MX2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A
Authority
MX
Mexico
Prior art keywords
carbinols
peri
reducing
symptom
risk
Prior art date
Application number
MX2015007916A
Other languages
English (en)
Spanish (es)
Inventor
Thomas A Jordan
John Clifford Chabala
Ke-Qing Ling
William A Kinney
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of MX2015007916A publication Critical patent/MX2015007916A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
MX2015007916A 2012-12-20 2013-12-19 Peri-carbinoles. MX2015007916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740197P 2012-12-20 2012-12-20
PCT/US2013/076592 WO2014100425A1 (en) 2012-12-20 2013-12-19 Peri-carbinols

Publications (1)

Publication Number Publication Date
MX2015007916A true MX2015007916A (es) 2016-04-07

Family

ID=50979217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007916A MX2015007916A (es) 2012-12-20 2013-12-19 Peri-carbinoles.

Country Status (14)

Country Link
US (1) US9604997B2 (OSRAM)
EP (1) EP2935220A4 (OSRAM)
JP (1) JP2016503797A (OSRAM)
KR (1) KR20150118106A (OSRAM)
CN (1) CN105073714A (OSRAM)
AU (1) AU2013361314A1 (OSRAM)
CA (1) CA2896032A1 (OSRAM)
CL (1) CL2015001754A1 (OSRAM)
HK (1) HK1217325A1 (OSRAM)
IL (1) IL239178A0 (OSRAM)
MX (1) MX2015007916A (OSRAM)
RU (1) RU2015120478A (OSRAM)
SG (1) SG11201504859YA (OSRAM)
WO (1) WO2014100425A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP6266023B2 (ja) 2013-01-25 2018-01-24 アルデイラ セラピューティクス, インコーポレイテッド 黄斑変性症の処置における新規トラップ
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
HK1256143A1 (zh) * 2015-08-21 2019-09-13 Aldeyra Therapeutics, Inc. 醛結合物和其用途
CN109069530A (zh) 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CN109640983A (zh) * 2016-08-22 2019-04-16 奥尔德拉医疗公司 醛捕获化合物和其用途
CN110431130A (zh) 2017-03-16 2019-11-08 奥尔德拉医疗公司 多晶型化合物和其用途
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス, インコーポレイテッド 眼科用製剤およびその使用
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
MX2023000263A (es) 2020-07-16 2023-03-29 Dermavant Sciences GmbH Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
AU723758B2 (en) 1996-08-01 2000-09-07 Dow Agrosciences Llc 4-substituted quinoline derivatives having fungicidal activity
EP0980362B1 (de) 1997-05-02 2006-08-16 Schering Aktiengesellschaft Substituierte heterocyclen und deren verwendung in arzneimitteln
JP2004500308A (ja) 1998-03-12 2004-01-08 ノボ ノルディスク アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
JP4564920B2 (ja) 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005035506A1 (ja) 2003-10-15 2005-04-21 Ube Industries, Ltd. 新規インダゾール誘導体
ZA200604403B (en) 2003-11-20 2007-09-26 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
AU2005215778B2 (en) 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
US20070287716A1 (en) * 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
BRPI0710737A2 (pt) * 2006-04-14 2011-05-10 Prana Biotechnology Ltd uso de compostos pb-10 33 éteis para o tratamento de degeneraÇço macular relacionada À idade (amd), assim como referidos compostos
AU2007280984A1 (en) * 2006-07-25 2008-02-07 Envivo Pharmaceutical Inc. Quinoline derivatives
WO2009045479A1 (en) 2007-10-05 2009-04-09 Acucela Inc. Alkoxy compounds for disease treatment
BRPI0917634A2 (pt) 2008-08-12 2015-11-17 Sirtris Pharmaceuticals Inc benzoxazolas, benztiazolas e análogos relacionados como moduladores de sirtuína
WO2010133672A1 (en) * 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
CN103562186B (zh) 2011-01-12 2017-02-15 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
CN103442735B (zh) 2011-01-31 2016-11-09 特米拉公司 用于减轻技术领域中所不希望的医学状况的有效要素
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP6266023B2 (ja) 2013-01-25 2018-01-24 アルデイラ セラピューティクス, インコーポレイテッド 黄斑変性症の処置における新規トラップ
EP3151818A4 (en) 2014-06-04 2018-05-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders

Also Published As

Publication number Publication date
KR20150118106A (ko) 2015-10-21
CL2015001754A1 (es) 2015-11-06
SG11201504859YA (en) 2015-07-30
EP2935220A4 (en) 2016-04-27
US9604997B2 (en) 2017-03-28
CN105073714A (zh) 2015-11-18
HK1217325A1 (zh) 2017-01-06
RU2015120478A (ru) 2017-01-25
AU2013361314A1 (en) 2015-07-02
US20150344432A1 (en) 2015-12-03
EP2935220A1 (en) 2015-10-28
JP2016503797A (ja) 2016-02-08
IL239178A0 (en) 2015-07-30
WO2014100425A1 (en) 2014-06-26
CA2896032A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2015007916A (es) Peri-carbinoles.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
PH12017502141A1 (en) Compounds and their methods of use
IN2015DN01156A (OSRAM)
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12015501385A1 (en) Autotaxin inhibitors
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
IN2015DN01151A (OSRAM)
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX362879B (es) Usos novedosos.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
MX365315B (es) Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
PH12014502065A1 (en) Vesicular formulations
IN2014DN08443A (OSRAM)
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
PH12015502703A1 (en) Pharmaceutical compositions
IN2014DN10683A (OSRAM)
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy